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Abstract
Background: Serological immunoassays that can identify protective immunity against 
SARS-CoV-2 are needed to adapt quarantine measures, assess vaccination responses, 
and evaluate donor plasma. To date, however, the utility of such immunoassays remains 
unclear. In a mixed-design evaluation study, we compared the diagnostic accuracy of 
serological immunoassays that are based on various SARS-CoV-2 proteins and 
assessed the neutralizing activity of antibodies in patient sera. 
Methods: Consecutive patients admitted with confirmed SARS-CoV-2 infection were 
prospectively followed alongside medical staff and biobank samples from winter 
2018/2019. An in-house enzyme-linked immunosorbent assay utilizing recombinant 
receptor-binding domain (RBD) of the SARS-CoV-2 spike protein was developed and 
compared to three commercially available enzyme-linked immunosorbent assays 
(ELISAs) targeting the nucleoprotein (N), the S1 domain of the spike protein (S1) and a 
lateral flow immunoassay (LFI) based on full-length spike protein. Neutralization assays 
with live SARS-CoV-2 were performed.
Results: One-thousand four-hundred and seventy-seven individuals were included 
comprising 112 SARS-CoV-2 positives (defined as a positive real-time PCR result; 
prevalence 7.6%). IgG seroconversion occurred between day 0 and day 21. While the 
ELISAs showed sensitivities of 88.4% for RBD, 89.3% for S1, and 72.9% for N protein, 
the specificity was above 94% for all tests. Out of 54 SARS-CoV-2 positive individuals, 
96.3% showed full neutralization of live SARS-CoV-2 at serum dilutions ≥1:16, while 
none of the 6 SARS-CoV-2 negative sera revealed neutralizing activity.
Conclusions: ELISAs targeting RBD and S1 protein of SARS-CoV-2 are promising 
immunoassays which shall be further evaluated in studies verifying diagnostic accuracy 
and protective immunity against SARS-CoV-2.
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Introduction
Governments worldwide are facing a unique challenge: to save thousands of lives 
threatened by coronavirus disease 2019 (COVID-19), while minimising economic and 
social damage caused by lockdown and other strict measures. Serological 
immunoassays will play a central role in addressing these challenges for the following 
reasons1. First, serological tests might improve the rate of diagnosis as real-time RT-
PCR is associated with a high number of false-negative results due to pre-analytical and 
other issues2. Second, antibody assays may support intensive surveillance measures 
such as universal testing, active case-finding, contact tracing, and linking clusters and 
thereby may facilitate an exit strategy from lockdown3-6. Third, immunoassays are 
important to identify individuals with previous severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection who have recovered and to enable adjustment of 
quarantine measures and physical distancing. Fourth, medical staff with protective 
immunity against SARS-CoV-2 might be identified and allocated to critical tasks with 
highly contagious patients. And fifth, vaccination responses in clinical studies could be 
more effectively monitored. Thus, global authorities including the World Health 
Organisation strongly encourage studies that investigate performance and application of 
serological tests for COVID-19. 
Various receptors including the angiotensin-converting enzyme 2 (ACE2) expressed by 
epithelial barrier tissues and immune cells play an important role in SARS-CoV-2 
infection as they represent a crucial entry point for the virus7-9. The sustained 
inflammatory immune response caused by SARS-CoV-2 infection contributes the 
development of clinical manifestations of COVID-19 and the related prothrombotic 
state9,10.  In patients with severe disease extensive activation of cytokine-secreting cells 
from the innate and adaptive immune system has been reported to result in a cytokine 
storm contributing to acute respiratory distress syndrome and multiorgan failure11-15. 
Antibody responses against different SARS-CoV-2 antigens have been described in 
serological samples of infected patients. Few patients with anti-viral antibodies have been 
identified in the first 5 days following symptom onset but the positive rate rapidly 
increases thereafter16,17. To date, antibody testing has focused primarily on two highly 
abundant structural antigens of SARS-CoV-2, specifically the nucleoprotein (N) protein A
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and the spike (S) protein18. While the N phosphoprotein ensures the linkage of the viral 
RNA to the membrane19, the S glycoprotein binds to ACE2 and thereby initiates viral 
entry into the host cell13,20-22. Neutralizing antibodies (NAb) are typically generated 
against the S protein and often target the receptor binding domain (RBD)23,24. As 
demonstrated in a vaccination approach using inactivated virus, the RBD represents an 
immunodominant viral antigen since at least half of the detectable anti-S IgG antibodies 
were directed against the RBD25. In contrast, the amount of anti-N antibodies was 30-fold 
lower.
Lateral flow immunoassays (LFI)26,27 as well as enzyme linked immunosorbent assays 
(ELISA)28,29 have been developed but not yet adequately evaluated. While LFIs are 
remarkably fast and only require minutes to perform, significant concern regarding their 
sensitivity and specificity has been raised30. ELISAs are considered more robust but 
require highly specialized laboratories with the capacity to run automated high-throughput 
measurements. 
At the time of compiling this paper, the diagnostic performance of different 
immunoassays as well as their predictive value for protective immunity remains unclear. 
Before a broad implementation of immunoassays can be justified, the following points 
need to be carefully assessed in adequately powered and designed diagnostic studies: 
(1) diagnostic accuracy (or sensitivity/ specificity respectively) in the acute and subacute 
phase of the disease, (2) antibody kinetics over time in patients with confirmed COVID-
19, (3) extent of cross-reactivity with other pathogens and patients with autoimmune 
disorders, (4) reliability between different assay settings and material characteristics, as 
well as (5) correlate of protective immunity3. 
With the present study, we aimed to comprehensively establish the utility and diagnostic 
accuracy of serological immunoassays for SARS-CoV-2 infection and to explore 
protective immunity12 as predicted by such immunoassays in a mixed-method 
observational study of hospital inpatients as well as medical personnel.
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Methods
Study design, setting and population
International guidelines on study design were strictly followed31 and cross-sectional, 
prospective observational, as well as case-control designs were used. Participants were 
recruited via three different routes: (i) inpatients with a SARS-CoV-2 test result (real-time 
PCR; RT-PCR), (ii) medical personnel of the Inselspital, and (iii) residual material from 
patients stored at the Liquid Biobank Bern (www.biobankbern.ch). Inclusion criteria of 
inpatients are (i) hospitalisation in Inselspital, (ii) tested positive for SARS-CoV-2 using 
RT-PCR (nasopharyngeal swab), (iii) aged 18 or older and (iv) signed general consent 
(exemption was granted for a few patients). For this manuscript, only inpatients who had 
tested positive for SARS-CoV-2 with more than 4 days of residual material available were 
considered. The temporal pattern of antibody response and seroconversion rate was 
assessed in a subgroup of inpatients; the first 25 consecutive patients were selected. 
Inclusion criteria of medical personnel were (i) medical staff at Inselspital since February 
2020, (ii) aged 18 or older, and (iii) signed informed consent. The personnel were 
recruited via mailing lists. A limited number of fully anonymized, residual biobank 
samples were also used for the purpose of this study with the inclusion criterion of having 
been collected from inpatients between December 2018 and February 2019. A total of 54 
randomly selected sera from individuals who were tested positive in either of the three 
ELISA immunoassays as well as 6 negative controls were assessed in a live SARS-CoV-
2 neutralization assay (all collected in April 2020).
The University Hospital Bern (Inselspital) is one of the largest tertiary hospitals in 
Switzerland covering a catchment area of more than 1 million inhabitants. With several 
associated smaller hospitals, it provides the full spectrum of general as well as highly 
specialised medical services. More than 10,000 employees work at the Insel Gruppe AG.
The study was supported by the local COVID-19 task force. The study protocol was 
approved by the appropriate ethics committee and the authorities of the University 
Hospital and conducted in accordance with the Declaration of Helsinki. The manuscript 
was prepared according to the Standards for Reporting Diagnostic accuracy studies 
(STARD) guideline32.A
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Handling of samples and collection of data
Blood was taken following an established in-house protocol to ensure adequate 
preanalytical conditions and samples were collected using plastic syringes (serum or 
lithium heparin respectively, S-Monovette®, Sarstedt, Nümbrecht, Germany). Only 
residual material was used in the case of inpatients. Two tubes (serum and lithium 
heparin respectively) were drawn in the case of medical personnel. Samples were 
immediately transported to the central laboratory, processed using a GLP laboratory track 
and centrifuged within 30 minutes with an established protocol33. 
With regard to inpatients, pseudonymized demographical, clinical as well as laboratory 
data were extracted and transferred by the Insel Data Science Center (IDSC) from 
electronic patient documentation. Limited data were collected for the purpose of this sub-
study: age, gender, time interval since RT-PCR (nasopharyngeal swab). A positive 
SARS-CoV-2 RT-PCR result was used as additional inclusion criterion. With regard to 
medical personnel, a RedCap database survey was constructed collecting demographical 
data, COVID-19 symptoms (presence, extent and date), comorbidities and risk factors, 
professional exposure, and date of RT-PCR.
Generation of recombinant RBD protein
The S1 protein and RBD are regarded as ideal candidates for the development of 
diagnostic tests and vaccines targeting SARS-CoV-234. The pCAGGS plasmid containing 
the human codon-optimized sequence of the SARS CoV-2 S protein receptor binding 
domain (RBD, amino acids R319-F541) with native S signal sequence (amino acids M1-
S14) and a C-terminal hexahistidine tag was kindly provided by Prof. Florian Krammer.  
Plasmid DNA was prepared using the Gene Elute HP Plasmid Maxiprep Kit (Sigma-
Aldrich). Prior to transfection Expi293F cells (Thermo-Fisher) were grown to a density of 
3.0 x 106 cells/ml in culture medium (a mixture of 33% Expi293 and 66% FreeStyle-293 
media from Thermo-Fisher). For each liter of transfection, 0.5mg of plasmid DNA was 
diluted in 100ml of culture medium, mixed with 1.3ml FectoPro transfection reagent 
(Polyplus), and incubated for 10 minutes at room temperature prior to addition to cells. 
Immediately following transfection cells were supplemented with 100x D-glucose (400g/l) A
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and 100 x Valproic acid (300mM) boost solutions. Three days post transfection the cell 
culture supernatants were harvested by centrifugation at 7,000 x g for 15min. 
Supernatants were passed through a 0.22µm filter and 1:1 diluted with PBS containing 
10 mM imidazole. For purification of his-tagged RBD protein 5 ml Ni-NTA resin (HisPur 
NiNTA ThermoFisher) was washed three times with washing buffer (PBS with 10mM 
imidazole) and incubated on a stir plate at 4°C for 1 hour. Subsequently, the mixture was 
poured into a glass column with a frit and washed 3 times with 5 column volumes of 
washing buffer. The protein was then eluted three times with 15 ml PBS containing 
250mM imidazole. Elutions were pooled and dialyzed overnight against PBS using 3.5 
kDa cutoff SnakeSkin dialysis tubing. The final protein concentration was determined by 
NanoDrop measurement at A280. The quality of recombinant RBD protein was analyzed 
by SDS-PAGE and analytical size-exclusion chromatography. 
Development of an in-house ELISA
All ELISA assays were performed on a DSX automated ELISA system device (DYNEX 
Technologies). The in-house assay was prepared as follows: 96-well plates were coated 
overnight at 4°C with 100µl of 1µg/ml RBD protein in PBS. The following day, each well 
was blocked with 300µl of PBS/0.15% casein at 4°C until use and at least overnight. 
Subsequently plates were washed twice with PBS and 100µl sera were added at a 1:100 
dilution in PBS/0.15% casein for 1 hour at RT. After five washes with 300µl PBS/0.1% 
Tween 100µl of HRP-labeled secondary polyclonal anti-human IgM (Sigma, A0420) and 
anti-human IgG (Sigma, A0170) antibodies were added in a 1:10’000 dilution for 30 
minutes at RT. Again, the plates were washed 5 times with PBS/0.1% Tween and 100µl 
of TMB substrate solution (Sigma, T4444) was added for 15 minutes at RT. The 
development was stopped by adding 100µl of 0.5M H2SO4 and results were measured at 
OD450-620nm. All samples with an OD > 0.5 were assigned as positive.
Determination of commercially available immunoassays
Several commercial tests were conducted according to the manufacturers’ instructions. 
An ELISA produced by Euroimmun AG, Lübeck, Germany targeting the S1 protein as the A
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immobilized antigen for the detection of IgG antibodies was employed. Briefly, samples 
were diluted 1:100 in sample buffer and 100l of diluted samples, pre-diluted positive and 
negative controls, as well as pre-diluted calibrator were added for 1 hour at 37°C. After 
three wash steps with 300µl wash buffer, 100µl of HRP-labeled secondary anti-human 
IgG antibodies were added for 30 minutes at 37°C. The plates were washed again three 
times with wash buffer and 100µl of TMB solution was added for 20 minutes at RT. The 
development was stopped by adding 100µl of 0.5M H2SO4 and results were measured at 
OD450-620nm. Antibody values were expressed as a ratio (ODsample/ODcalibrator). All 
samples with a ratio >1.1 were assigned as positive.
A different ELISA determining IgG and IgM antibodies against N (Epitope Diagnostics 
Inc., San Diego, CA) was used as follows. For IgG, samples were added to the 
immobilized antigen in a 1:100 dilution (in IgG sample diluent) for 30 minutes at RT. After 
washing the plates five times with diluted wash concentrate, 100µl of HRP-labeled 
secondary anti-human IgG antibodies were added for 30 minutes at RT. The plates were 
washed again five times with diluted wash concentrate and 100µl of TMB solution was 
added for 20 minutes at RT. The development was stopped by adding 100µl of 0.5M 
H2SO4 and results were measured at OD450-620nm. Cut-off for a positive reaction was 
calculated by the following formula: 1.1*(mean ODNegative Control + 0.18). For IgM, 10µl of 
undiluted samples were added to the immobilized anti-IgM in the microtiter plate, and 
100µl of IgM Sample Dilution buffer were added and incubated at 37°C for 30 minutes. 
After washing the plates five times with diluted wash concentrate, 100µl of HRP-
conjugated SARS-CoV-2 antigen was added for 30 minutes at 37°C. The plates were 
washed again five times with diluted wash concentrate and 100µl of TMB solution was 
added for 20 minutes at RT. The development was stopped by adding 100µl of 0.5M 
H2SO4 and results were measured at OD450-620nm. Cut-off for positive reaction was 
calculated by the following formula: 1.1*(mean ODNegative Control + 0.10).
A lateral flow rapid test determining IgG and IgM antibodies against the recombinant S 
protein (Autobio Diagnostics Co, LTD, Zhengzhou, China) was used according the 
instructions. Briefly, 5l of serum or heparin plasma, or alternatively, 10l of whole 
capillary blood were added to both IgM and IgG cavities of the cassette. 60l of reaction A
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buffer were added and reactions were visually read after 15 minutes and assessed as 
negative, equivocal or positive reactions. 
Determination of real-time PCR
Patient sample material was obtained by performing nasopharyngeal swabs using Copan 
FLOQSwabs and Copan UTM Viral Transport medium (Copan, Brescia, Italy). Collected 
patient sample material was transported to the laboratory at room temperature and stored 
at 4°C until processing. For nucleic acid testing (NAT), three different methodologies 
were used in the respective time period of sample collection. An laboratory developed 
test (LDT) RT-PCR workflow based on the published protocol of Corman et al. was 
utilised for pan-Sarbecovirus E-gene detection35 followed by the detection of the SARS-
CoV-2 specific RdRP-gene. Additionally, two commercial, fully automated workflows, the 
Seegene Allplex 2019-nCoV Assay (Seegene, Seoul, Korea) and the Roche cobas® 
SARS-CoV-2 Assay (Roche Diagnostics, Rotkreuz, Switzerland) were used.
RNA for the LDT RT-PCR workflow was extracted after inactivation of patient samples 
using AVL buffer (Qiagen, Hilden, Germany) in a ratio of 200 µl sample + 800 µl buffer 
using the MagNA Pure 24 system (Roche Diagnostics, Rotkreuz, Switzerland) or ELITe 
InGenius SP 1000 extraction cassette on an InGenius System (Elitech, Torino, Italy) and 
eluted in 100 μL. Alternatively, an adapted cobas 4800 workflow used the extraction 
chemicals and protocol for the IVD workflow for the  cobas HIV-1 Assay for the cobas® 
4800 System (Roche Diagnostics, Rotkreuz, Switzerland) in which 400 μL non-
inactivated patient sample eluted in 100 μL was performed. RNA for the Allplex 2019-
nCoV workflow was extracted according to the manufacturer's instructions using 
Seegene's STARlet IVD workflow. RNA for cobas® SARS-CoV-2 was extracted 
according to the manufacturer's instructions using Roche's cobas® 8800 system.
Seegene Allplex 2019-nCoV and cobas® SARS-CoV-2 were performed according to the 
manufacturer's instructions using a STARlet IVD System or a cobas 8800 system, 
respectively.
For the LDT E-gene and RdRP-gene detection the following was used: RT-PCR assays 
RNA Process Control Kit (Roche Diagnostics, Rotkreuz, Switzerland; Cat. No. 07 099 A
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592 001) containing LightCycler Multiplex RNA Virus Master for reverse transcription / 
amplification, RNA Process Control as an internal control for extraction and PCR and 
RNA Process Control Detection Assay (proprietary Cy5-labeled probe and primers) for 
RNA Process Control detection. A 20 μL reaction contained 5 μL of RNA, 1.0 μL of 20x 
RNA Process Control Detection Assay, 0.1 μL of 200x RT Enzyme Solution and 4.0 μL of 
5x RT-qPCR Reaction Mix. For E-gene detection, primer/probe sequences and 
concentrations were used according to the published protocol35.  Primer/probe 
sequences and concentrations used for the LDT-RdRP Assay are as follows: RdRP1-F1; 
AAATGGTCATGTGTGGCGGT; 900 nM / RdRP1-R2; ATTAACATTGGCCGTGACAGCT; 
900 nM / RdRP1-P3mgb; FAM-CTCATCAGGAGATGCC-MQ530; 100 nM / RdRP2-F4; 
ATGGTCATGTGTGGCGGC; 900 nM / RdRP2-R5; GCATTTACATTGGCTGTAACAGCT; 
900 nM / RdRP2-P6mgb; HEX-CATCATCCGGTGATGCT-MQ530; 100 nM. Primer/probe 
system RdRP1 is specific for detection of SARS-CoV-2 and primer/probe system RdRP2 
is specific for detection of SARS-CoV-1. All oligonucleotides were synthesized and 
provided by Mycrosynth AG (Balgach, Switzerland). Thermal cycling was performed at 
50 °C for 10 min for reverse transcription, followed by 95 °C for 30 sec and 45 cycles of 
95 °C for 5 s, 60 °C for 30 s. A Roche Light Cycler 480 instrument was used for 
amplification and fluorescence detection (Roche Diagnostics, Rotkreuz, Switzerland). 
Definition of diagnoses
As the primary reference standard test, a positive RT-PCR test from a nasopharyngeal 
swab was defined as ‘confirmed SARS-CoV-2 infection’ (SARS-CoV-2+). In light of the 
limitations of this test, it was used as the only reference standard for the purpose of this 
first analysis. Sensitivity analyses using additional reference standards will be employed 
in subsequent phases of this study (focusing on different clinical manifestations). ‘SARS-
CoV-2 negative’ (SARS-CoV-2-) was defined as (i) a negative RT-PCR result in all 
nasopharyngeal swabs conducted, or (ii) RT-PCR not performed (because all patients 
and medical staff would have been tested in case of symptoms according to applicable 
regulations). Biobank samples from Winter 2018/2019 were also categorized as negative. 
Comorbidities and risk factors, which will be used as covariables in subsequent phases of 
this study, will be extracted from electronic patient records and asked in the RedCap A
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survey of medical staff, assuming that classifications have been made according to 
current guidelines.
Live SARS-CoV-2 neutralization assay
Serum samples were tested for the presence of neutralizing antibodies determined by the 
inhibition of virus-induced cytopathic effect (CPE). Briefly, sera from 56 SARS-CoV-2 
positive individuals (inpatients as well as medical personnel) and 6 sera from SARS-CoV-
2 negative individuals (medical personnel) were incubated at 56°C for 30 min for 
complement inactivation, centrifuged at 13,000 rpm for 10 min and diluted 1:8 in cell 
culture medium (MEM Eagle with EBSS, 20mM HEPES with 0.85 g/l NaHCO3, 
supplemented with 2% FCS, penicillin (100 U/ml), streptomycin (100 mg/ml), and L-
glutamine (2 mmol/l); all from Bioswisstec AG, Schaffhausen, Switzerland). Of the 1:8 
serum dilutions, 112.5 µl were transferred into a 96-well plate in duplicates. From there, 
12.5 µl was used to produce a 5-fold serial dilution in 50 µl culture medium; 50 µl was 
transferred to another row to control for serum toxicity on control cells. Then, serially 
diluted sera were mixed with 50 µl/well of diluted virus culture corresponding to 100 
TCID50 of infectious SARS-CoV-2 (BetaCoV/France/IDF0372/2020). The serum/virus 
mixture was incubated for 1 h at 37°C and subsequently transferred to a confluent 96-
well-plate with Vero-E6 cells. Plates were incubated for 3 days at 37°C with CO2 bags 
and CPE was determined by crystal violet staining.  Wells which showed no CPE as 
judged by a complete cell layer were rated (-) and wells showing signs of CPE were rated 
(+). Full neutralization titer was determined as the serum dilution were no signs of CPE (-
) was observed in both duplicates. The strain BetaCoV/France/IDF0372/2020 was 
supplied by the National Reference Centre for Respiratory Viruses hosted by Institut 
Pasteur (Paris, France) and headed by Pr. Sylvie van der Werf. The human sample from 
which strain BetaCoV/France/IDF0372/2020 was isolated has been provided by Dr. X. 
Lescure and Pr. Y. Yazdanpanah from the Bichat Hospital, Paris, France. Moreover, the 
strain BetaCoV/France/IDF0372/2020 was supplied through the European Virus Archive 
goes Global (Evag) platform, a project that has received funding from the European 
Union’s Horizon 2020 research and innovation program under grant agreement No 
653316.A
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Statistical analysis
Descriptive statistics have been used to illustrate the distribution of immunoassay test 
results in patients and medical staff with and without SARS-CoV-2 infection and to show 
temporal patterns. Days until seroconversion were plotted following the occurrence of 
symptoms or a positive RT-PCR result, respectively. To calculate measures of diagnostic 
accuracy, we pooled all patients and medical personnel being aware that the composition 
of this cohort is artificial. The time point since RT-PCR or symptoms respectively was not 
taken into account because criteria for a clear cut off are lacking. Two-by-two tables were 
generated, sensitivities and specificities calculated, and receiver-operating-characteristics 
(ROC) curves plotted as well as c-statistics performed for comparative purposes. A 
formal power analysis has not been performed, but we have included as many inpatients 
and medical staff as possible for the purpose of this preliminary analysis and generated 
confidence intervals as appropriate. Analyses were carried out using the Stata 14.2 
statistical software (StataCorp. 2014. Stata statistical software: Release 14. College 
station, Tx: StataCorp LP). Figures were created using Prism 6 (GraphPad Software, 
Inc., LaJolla, California, United States).
Results
Characteristics of participants
At University Hospital Bern we first established a carefully designed mixed-method 
diagnostic accuracy study (Fig. 1). Forty-two inpatients with confirmed SARS-CoV-2 
infection as defined by a positive RT-PCR (nasopharyngeal swab) with more than 4 days 
of residual material were available and 202 data points have been analyzed. Median age 
was 66 years (range 24 to 86), 21% of the patients were female. The median number of 
days of symptoms before hospitalisation was 7 (range 0 to 18); 48% of the patients were 
admitted to the intensive care unit. More detailed patient characteristics are reported in 
supplementary Table 1. We additionally included the first 1403 individuals who 
participated in the cohort of medical staff for the purpose of this analysis. Out of these 
individuals, 70 were positive for SARS-CoV-2 in RT-PCR, and 75% of SARS-CoV-2 
positive individuals (n=53) reported COVID-19 associated symptoms (fever, A
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breathlessness, coughing, or loss of smell). The median age was 39 (range 23, 65), 
60.7% of the individuals were women (n=851). Further, we included residual serum 
samples of patients stored at the Liquid Biobank Bern (n=32). These samples were 
frozen between December 2018 and February 2019 before the global outbreak of SARS-
CoV-2 infections.
Analytical characteristics of in-house ELISA (RBD)
Recombinantly expressed RBD has been used to establish an in-house ELISA for the 
detection of IgM and IgG anti-SARS-CoV-2 antibodies in human serum samples 
(supplementary Fig. 1a,b). Optimal serum dilutions were determined by titration of sera 
derived from six SARS-CoV-2+ and six SARS-CoV-2- individuals. The serum dilution of 
1:100 allowed efficient discrimination between positive and negative outcome 
(supplementary Fig. 2). After automatization on a DYNEX DSX device, the intra-assay 
(within-run) and inter-assay (day-to-day) precisions of the in-house RBD ELISA was 
assessed (supplementary Fig. 3a-d, supplementary Table 2a,b and supplementary 
Table 3a,b). We further compared serum and heparin-plasma (supplementary Fig. 
3e,f). Overall, the in-house RBD ELISA assay showed high intra- and inter-assay 
reproducibility and demonstrated a high degree of agreement between plasma and 
serum samples. 
Temporal pattern of antibody response as measured by different immunoassays
Among a subgroup of 25 SARS-CoV-2+ inpatients, seroconversion for IgM and IgG 
antibodies was observed between day 0 and day 21 after the RT-PCR result and 
between day 2 and day 21 after the start of symptoms (Fig. 2). Interestingly, IgM and IgG 
antibody responses against RBD and S1 were substantially more pronounced as 
compared to N. Assessment of the longitudinal dynamics of patient sera revealed a 
marked and consistent increase of IgG antibodies for RBD and S1 (Fig. 3a). IgM 
antibodies were measured in the RBD and N ELISA and detectable at least for two 
weeks after seroconversion (Fig. 3b). Interestingly, the individual temporal IgG and IgM 
patterns showed a high degree of inter-individual variability with one group of patients A
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displaying high antibody responses already at the time of hospitalization, while a second 
group seroconverted within the first week of hospitalization and a third group that 
mounted only a week response within the time of analysis (supplementary Fig. 4 and 
supplementary Fig. 5). Additionally, we analysed serum samples from 32 inpatients 
between December 2018 and February 2019 (biobank samples from winter 2018/2019). 
Of these samples, all were negative for anti-RBD IgM and IgG, as well as anti-S1 IgG. 
However, two biobank samples tested positive for anti-N IgG (ELISA; 6.2%), and one 
tested positive for anti-N IgM (ELISA; 3%). All samples were negative for anti-S IgG and 
IgM (100%) as tested by LFI. 
Diagnostic accuracy
The pooled study population consisted of 1477 individuals, 112 of whom tested as RT-
PCR positive (prevalence 7.6%). Sera from all individuals were tested in the three 
different ELISA setups for IgG and IgM anti-SARS-CoV-2 antibodies (Fig. 4a). A 
subgroup of samples (n=159) was additionally assessed on LFI (Fig. 4b). Both assay 
formats showed high specificity above 94% for IgG and IgM measurements 
(supplementary Table 4). However, the sensitivity between assays and formats varied 
considerably. The highest sensitivities were reached for IgG measurements with the S1 
(89.3%) and RBD (88.4%) ELISA, followed by IgG measurements on N (72.9%) ELISA. 
Sensitivities for IgM measurements were all considerably lower for both ELISA and LFI 
formats, which could be due to the more transient detectability of IgM upon infection.
To detect potential sources of variability, we additionally studied the antibody response in 
salient subgroups of RT-PCR positive individuals (Fig. 4c). First, higher IgG antibodies 
were found in inpatients compared to medical personnel, potentially reflecting the higher 
proportion of patients with severe disease (RBD ELISA; mean OD difference 0.44; SD 
0.19; p=0.01). Second, no significant difference was found between individuals with and 
without COVID-19 symptoms (mean OD difference 0.11; SD 0.24; p=0.64). Third, the IgG 
response was higher in hospitalized patients compared to outpatients (0.50; SD 0.18; 
p=0.005), but not in ventilated patients compared to hospitalized patients (mean OD 
difference 0.08; SD 0.23; p=0.72). Fourth, IgG response was higher in patients above 50 
years than patients below (0.54; SD 0.25; p=0.03).A
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In the tested inpatient population, we observed three “false-negative” (negative in S1 
ELISA despite positive RT-PCR) outcomes. Among three false-negative inpatients (P07, 
P041, and P042), two were measured at an early time-point (Patient 7 and 41), and one 
patient (P042) might have experienced seroconversion at a very late time-point because 
of a significant increase of antibody titers at day 24 (supplementary Fig. 3 and 
supplementary Fig. 4). In the assessed hospital staff, seven were classified as “false-
negative”. All of these reported mild diseases and had symptoms clearly associated with 
COVID-19 (fever, breathlessness, cough, and loss of taste or smell). Twenty-two 
individuals in the hospital staff group tested “false-positive” (positive S1 ELISA results 
despite negative RT-PCR). Fourteen of them experienced one or more symptoms clearly 
associated with COVID-19. The remaining eight individuals were clearly positive in at 
least three assays. All other individuals were either classified as “true-positive” (positive 
in S1 ELISA, and positive in RT-PCR), or as “true-negative” (negative in S1 ELISA, and 
negative in RT-PCR).
In terms of performance, the calculated area under the receiver operating characteristic 
(ROC) curve for IgG measurements was 0.96 (95% CI: 0.94 to 0.98) in the RBD, 0.98 
(95% CI: 0.97 to 0.99) in the S1, and 0.91 in the N (95% CI: 0.86 to 0.95) ELISA (Fig. 
5a), while for IgM measurements it reached 0.86 (95% CI: 0.81 to 0.90) for RBD ELISA  
and 0.84 (95% CI: 0.80 to 0.89) for N ELISA (Fig. 5b).
SARS-CoV-2 neutralization corresponds with ELISA positivity
A total of 54 randomly selected sera from individuals who were tested positive in either of 
the three ELISA immunoassays as well as 6 negative controls were assessed in a live 
SARS-CoV-2 neutralization assay using ACE2-expressing Vero-E6 cells (34 inpatient 
samples, and 26 samples of medical personnel). Full neutralization of viral infection has 
been determined based on 100% inhibition of the cytopathic effect in a serial dilution of 
the sera (supplementary Fig. 6). The means of highest serum dilutions at which full 
neutralization was observed correlated remarkably well with the measured antibody 
responses in the ELISA immunoassays (Fig. 6a-c). Importantly, 96.3% of the sera from 
ELISA positive individuals showed full inhibition at serum dilutions ≥1:16. The two sera 
that did not show neutralization (P037 and P042) were drawn at an early time point A
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where the patients did not yet show antiviral antibodies. Both patients, however, fully 
neutralized the virus after seroconversion at a later time point (Fig. 6d). Further, all 6 
sera from ELISA negative individuals showed no neutralizing activity. Of note, one or two 
ELISA assays were negative in 17 samples with full neutralization.
Discussion
We report first results of a large, mixed-design evaluation study which was implemented 
to compare the diagnostic accuracy of serological immunoassays for SARS-CoV-2 
antibodies. While the time to seroconversion varied substantially between infected 
individuals, the mounted IgG responses were robust and stable over time in all assays 
relying on RBD, S1 as well as N. With regards to the ELISA assays, the overall 
diagnostic accuracy was adequate with a high specificity. Some “false-positive” results 
are likely due to a rather narrow diagnostic window and limited sensitivity of the RT-PCR 
as well as asymptomatic disease course 36. “False-negative” results may be caused by a 
long seroconversion period observed in some patients and mild disease course in other 
individuals. The accuracy measures of LFI and N were inferior compared to ELISA 
targeting S1 and RBD. Strikingly, there is a high degree of correlation between antibody 
responses to these viral surface proteins and the neutralizing activity against live SARS-
CoV-2.
A few other studies have previously assessed the diagnostic accuracy of serological 
immunoassays. Recently, Long and colleagues studied the antibody response in 285 
patients with COVID-19 using a magnetic chemiluminescent immunoassay. 37 In 
accordance with their results, we observed high inter-individual variation in the time to 
seroconversion. In contrast to their study, we confirmed these findings with an 
appropriate diagnostic accuracy protocol using different serological immunoassays. In 
another case-control study, Infantino et al. analyzed 61 COVID-19 inpatient samples and 
64 selected patients collected before 2020 using a magnetic chemiluminescent 
immunoassay38. In agreement with their results, we found limited sensitivity but high 
specificity of the serological SARS-CoV-2 immunoassays. In further study conducted at 
the Geneva University Hospital, 181 samples of COVID-19 patients were included as well 
as 176 controls collected before 2020, and analyzed with the same S1 ELISA that we A
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used in our study. Similar to our results they report a high specificity for IgG, particularly 
with an adjusted cut-off value39. In line with other studies the accuracy and performance 
LFIs was rather weak40,41. 
The study presented here adds important value to previous reports as it (i) was designed 
as a comprehensive diagnostic accuracy study combining different research methods, (ii) 
directly compares major assay approaches, (iii) was fully approved by all appropriate 
authorities, (iv) was independently conducted at a University Hospital, (v) includes 
comprehensive neutralization experiments with live virus and (vi) fully describes all 
clinical and technical procedures. Additionally, the study design allows straight forward 
expansion to automated immunoassay testing. On the other hand, a potential 
shortcoming of this study is the limited number of tested individuals. Besides, the 
observation period was limited to approximately one month, making it impossible to 
conclude beyond this time point.
Our findings emphasize that serological immunoassays are an important diagnostic tool 
in the context of the current COVID-19 pandemic. While positive ELISA test results 
correctly identified SARS-CoV-2 infected individuals with high probability in our study, the 
results also revealed that not all cases could be captured. This confirms other studies 
reporting that many asymptomatic and mild cases of SARS-CoV-2 infections do not lead 
to a detectable seroconversion 42,43. In this study, we further confirm that a general 
timepoint of seroconversion cannot be predicted. However, longitudinal tracing of patients 
reveals individual seroconversion. So far, the extent of cross-reactivity to other pathogens 
appears low, but this must as well be addressed in larger patient populations.
Moreover, our results from the live SARS-CoV-2 neutralization assays strongly indicate 
the presence of protective antibodies in 96.3% of tested sera within the one-month follow-
up period assessed in this study. Previous work in non-human primates have reported 
that serum dilutions of 1:16 were protective for re-infection with SARS-CoV-244. Our 
findings are in line with previous reports describing a close correlation of antibody 
responses against RBD, S1 and N protein of SARS-CoV-2 with full neutralizing activity 
and indicate that such serological tests might even be used to predict protective immunity 
in near future45,46. To draw further conclusions, however, SARS-CoV-2 positive patients 
have to be followed over an extended time period in future studies.A
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In line with previous studies47, we observed that the antibody response is more 
pronounced in patients with severe disease than patients without (Figure 4, panel C; 
inpatients, hospitalized patients, older patients). However, the response was similar in 
patients with mechanical ventilation and hospitalized patients. This is most likely due to 
limitations in sensitivity, which does not contradict our general observations.
In summary, we report the first results of a large, mixed-design evaluation study that has 
been conducted in an independent academic setting at the University Hospital Bern to 
assess the diagnostic accuracy of various immunoassays to determine antibody 
responses against SARS-CoV-2. While antibody responses of individual COVID-19 
patients against RBD and S1 protein were similar, a weaker reactivity against N protein 
became apparent. The time to seroconversion varied substantially between COVID-19 
patients but the IgG response was robust and stable in all three ELISA setups. Their 
overall diagnostic accuracy was adequate with a high specificity but limited sensitivity. 
The antibody responses measured in these ELISAs correlated remarkably well with 
SARS-CoV-2 neutralizing activity of the sera. On the other hand, accuracy measures of S 
protein based LFIs were poor. Together, our results emphasize that appropriate 
serological immunoassays represent a valuable tool to identify a good portion of patients 
with previous SARS-CoV-2 infection, will help to facilitate exit strategies from lockdown 
and might even be used to predict immunity to SARS-CoV-2 in near future.
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Figure Legends
Figure 1: Flowchart of study cohort and study design. Only RT-PCR positive 
inpatients were considered in the current phase of the study (*). Consecutive patients 
admitted with confirmed SARS-CoV-2 infection were prospectively followed alongside 
medical staff and biobank samples from winter 2018/2019 (pooled data were used for 
calculation of diagnostic accuracy). Boxes with a dashed outline are not yet completed. 
RT-PCR, real-time PCR; ELISA, enzyme linked immunosorbent assay; LFI, lateral flow 
immunoassay.
Figure 2: Seroconversion rate since symptoms and positive RT-PCR result. The 
percentage of consecutive patients (n = 25) positively tested for anti-SARS-CoV-2 protein 
antibodies is shown as a function of time (since symptom onset: red; since positive RT-
PCR result: blue line) for IgG in the RBD (a), IgG in the S1 (b), IgG in the N (c), IgM in the 
RBD (d) and IgM in the N ELISA (e). Curves were calculated using non-linear fitting. 
Figure 3: Temporal pattern of antibody responses against SARS-CoV-2 since 
seroconversion. IgG and IgM antibody responses of consecutive patients (n = 25) as 
measured by three ELISAs targeting different proteins of SARS-CoV-2: (a) IgG against 
the receptor binding domain (RBD), the S1 domain of the spike protein (S1) and the 
nucleoprotein (N); (b) IgM against the receptor binding domain (RBD) and the 
nucleoprotein (N). Data is shown as mean ± SEM. Curves were calculated using non-
linear fitting.
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Figure 4: Distribution of immunoassay results among SARS-CoV-2 positive and 
negative individuals. Consecutive patients admitted with confirmed SARS-CoV-2 
infection were prospectively followed alongside medical staff and biobank samples from 
winter 2018/2019 (pooled data). (a) IgG and IgM responses against the receptor binding 
domain (RBD), the S1 domain of the spike protein (S1) and the nucleoprotein (N) of 
SARS-CoV-2 in SARS-CoV-2 positive (n = 112) and negative (n = 1365) individuals as 
measured by ELISA. Data are shown as individual data points with a box and whiskers 
plot indicating minimum to maximum response. (b) IgG and IgM responses against the 
S1 domain of the spike protein of SARS-CoV-2 as measured by LFI in RT-PCR positive 
and negative patients. Positive (red), weak positive (green) and negative (blue) 
responses are shown as percentage of the whole in a pie chart. (c) Antibody response in 
salient subgroups of RT-PCR positive individuals (inpatients vs. medical personnel, 
patients with symptoms vs. patients without, hospitalized patients vs. outpatients, patients 
with ventilation vs. patients without, patients above 50 years vs. patients below 50 years 
of age).
Figure 5: Accuracy of three different SARS-CoV-2 ELISAs. Receiver operating 
characteristics curves of (a) IgG and IgM (b) measurements against the receptor binding 
domain (RBD), the S1 domain of the spike protein (S1) and (c) the nucleoprotein (N) of 
SARS-CoV-2 in SARS-CoV-2 positive (n = 112) and negative (n = 1365) individuals (N 
was conducted in 159 individuals only).
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Figure 6: Live SARS-CoV-2 neutralisation. Individual antibody responses (grey dots) 
against RBD (a), S1 (b) and N protein (c) in sera of 54 SARS-CoV-2 positive and 6 
SARS-CoV-2 negative individuals as measured by ELISA are shown together with the 
corresponding serum dilution at which full neutralisation of SARS-CoV-2 is observed. 
Non-linear curve fitting was calculated based on the means of each serum dilution group 
(red circles). (d) Changes in the serum dilution for full neutralisation of SARS-CoV-2 over 
time is depicted for seven individual SARS-CoV-2 patients. no NT: no neutralisation 
detectable.
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Supplementary Figure Legends
Figure S1: Purity and quality check of recombinant RBD protein. (a) SDS-PAGE 
image of recombinantly expressed and his-tag purified RBD protein. The molecular 
weight marker (lane 1) is shown next to purified RBD protein (lane 2). (b) An analytical 
size-exclusion chromatography histogram of purified RBD protein is depicted.
Figure S2: RBD ELISA establishment. Detection of anti-SARS-CoV-2 IgG (a) and IgM 
(b) antibodies in serially diluted sera of RT-PCR positive (closed circles) and negative 
(open circles) subjects. Direct comparison of IgG (c) and IgM (d) antibody responses in 
RT-PCR positive and negative samples at a 1:100 serum dilution. Statistical significance 
was calculated by Student’s t test. Data are shown as individual data points with mean 
values ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure S3: Validation of RBD ELISA. Intra-assay precision analysis of anti-RBD IgG (a) 
and IgM (b) antibodies with three samples containing different antibody titers at a 1:100 
dilution in 10 replicates. The inter-assay precision analysis for anti-SARS-CoV-2 IgG (b) 
and IgM (d) is shown for a 1:100 diluted serum sample that was run on eight different 
days in three ELISAs. Anti-RBD IgG (e) and IgM (f) antibodies were measured in serum 
and plasma from individual patients (n = 22). A linear regression analysis was performed.
Figure S4: Anti-SARS-CoV-2 IgG responses of individual COVID-19 patients. IgG 
responses of individual COVID-19 patients (n = 25) against the RBD protein (red), the S1 
domain of the spike protein (blue) and the nucleocapsid (green) of SARS-CoV-2 were 
longitudinally measured since time point of hospitalization. Curves were calculated using 
non-linear fitting.
Figure S5: Anti-SARS-CoV-2 IgM responses of individual COVID-19 patients. IgM 
responses of individual COVID-19 patients (n = 25) against the RBD protein (red) and the 
nucleocapsid (green) of SARS-CoV-2 were longitudinally measured since time point of 
hospitalization. Curves were calculated using non-linear fitting.A
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Figure S6: Live SARS-CoV-2 neutralization. (a) Representative pictures for the 
neutralizing activity of a COVID-19 negative and two COVID-19 positive sera in different 
dilutions. (b) Virus and cell controls without virus are shown. Individual IgG and IgM 
antibody responses (grey dots) against RBD (c) and N protein (d) in sera of 54 COVID-19 
positive and 6 COVID-19 negative individuals as measured by ELISA are shown together 
with the corresponding serum dilution at which full neutralization of SARS-CoV-2 is 
observed. Non-linear curve fitting was calculated based on the means of each serum 
dilution group (red circles). 
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